Yayın:
First-in-human tandem Terbium-161 and Actinium-225 PSMA radioligand therapy in metastatic castration-resistant prostate cancer

Sadeleştirilmiş öğe sayfası
dc.contributor.authorOmer Aras
dc.contributor.authorKezban Berberoğlu
dc.date.accessioned2026-05-20T10:16:52Z
dc.date.issued2026-02-02
dc.identifier.doi10.1007/s00259-026-07785-7
dc.identifier.issn1619-7070
dc.identifier.openalexW7127039227
dc.identifier.urihttps://hdl.handle.net/11421/39692
dc.identifier.urihttps://doi.org/10.1007/s00259-026-07785-7
dc.language.isoen
dc.relation.ispartofEuropean Journal of Nuclear Medicine and Molecular Imaging
dc.rightsrestrictedAccess
dc.subjectProstate cancer
dc.subjectRadioligand
dc.subjectGlutamate carboxypeptidase II
dc.subjectPCA3
dc.subjectMetastasis
dc.subjectRadiation therapy
dc.subject.sdg3
dc.subject.sdg2
dc.titleFirst-in-human tandem Terbium-161 and Actinium-225 PSMA radioligand therapy in metastatic castration-resistant prostate cancer
dspace.entity.typePublication

Dosyalar

Koleksiyonlar

Publications